| 12414985 |
Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Richie Khanna, Russell Gotschall |
2025-09-16 |
|
| 12246062 |
Recombinant human acid alpha-glucosidase |
Russell Gotschall, Richie Khanna, Yi Lun, Hing Char, Sergey Tesler +2 more |
2025-03-11 |
|
| 12064485 |
Disulfide bond stabilized polypeptide compositions and methods of use |
Ce Feng Liu |
2024-08-20 |
$34,042,000 |
| 11753632 |
Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Russell Gotschall |
2023-09-12 |
$33,366,000 |
| 11591583 |
Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Russell Gotschall |
2023-02-28 |
$41,155,000 |
| 11491243 |
Gene therapy constructs and methods of use |
Steven Tuske, Russell Gotschall, Ce Feng Liu |
2022-11-08 |
$19,439,000 |
| 11491211 |
Formulations comprising recombinant acid alpha-glucosidase |
Hing Char, Sergey Tesler, Wendy Sunderland, Enrique Diloné, Russell Gotschall |
2022-11-08 |
$19,439,000 |
| 11441138 |
Method for selection of high M6P recombinant proteins |
Russell Gotschall |
2022-09-13 |
$42,515,000 |
| 11278601 |
Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Richie Khanna, Russell Gotschall |
2022-03-22 |
$4,357,000 |
| 11097015 |
Disulfide bond stabilized polypeptide compositions and methods of use |
Ce Feng Liu |
2021-08-24 |
$37,430,000 |
| RE48608 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, John Flanagan, Xiaoyang Wu, Brandon Wustman |
2021-06-29 |
|
| 10961522 |
Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Russell Gotschall |
2021-03-30 |
$36,850,000 |
| 10874750 |
Gene therapy constructs and methods of use |
Steven Tuske, Russell Gotschall, Ce Feng Liu |
2020-12-29 |
$21,307,000 |
| 10857212 |
Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Richie Khanna, Russell Gotschall |
2020-12-08 |
$27,029,000 |
| 10813921 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Xiaoyang Wu, John Flanagan, Brandon Wustman |
2020-10-27 |
$34,166,000 |
| 10814008 |
Chemical crosslinkers |
— |
2020-10-27 |
$34,166,000 |
| 10660972 |
Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
— |
2020-05-26 |
$41,251,000 |
| 10512676 |
Formulations comprising recombinant acid alpha-glucosidase |
Hing Char, Sergey Tesler, Wendy Sunderland, Enrique Diloné, Russell Gotschall |
2019-12-24 |
$13,091,000 |
| 10227577 |
Method for selection of high M6P recombinant proteins |
Russell Gotschall |
2019-03-12 |
$35,472,000 |
| 10208299 |
Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Russell Gotschall |
2019-02-19 |
$28,659,000 |
| 9889203 |
Chemical crosslinkers |
— |
2018-02-13 |
$34,759,000 |
| 9821038 |
Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity |
— |
2017-11-21 |
$33,559,000 |
| 9566316 |
Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity |
— |
2017-02-14 |
$14,508,000 |
| 9545397 |
Method to predict response to pharmacological chaperone treatment of diseases |
Elfrida Benjamin, Xiaoyang Wu, John Flanagan, Brandon Wustman |
2017-01-17 |
$6,970,000 |
| 9545450 |
Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
— |
2017-01-17 |
$6,970,000 |